Pharmaceutical Preparations · NV · CIK 1133416
Develops carbohydrate-based therapies targeting galectin proteins for fibrotic diseases and cancer
Comparable business profile · signals at a glance
In the 90 days to Feb 6, 2026: 2 insiders bought $65K · 6 sold $5.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 6, 2026 | Eldred KaryDirector | Buy | 300 | $2.70 | $810 |
| Jan 6, 2026 | Lewis JoelPresident and CEO | Sell | 37,698 | $3.58 | $135K |
| Jan 6, 2026 | Jamil KhurramChief Medical Officer | Sell | 21,446 | $3.65 | $78K |
| Jan 6, 2026 | Callicutt Jack WChief Financial Officer | Sell | 20,354 | $3.67 | $75K |
| Jan 5, 2026 | Lewis JoelPresident and CEO | Sell | 27,731 | $3.91 | $108K |
| Jan 5, 2026 | Callicutt Jack WChief Financial Officer | Sell | 25,732 | $3.90 | $100K |
| Jan 5, 2026 | Jamil KhurramChief Medical Officer | Sell | 25,499 | $3.90 | $99K |
| Jan 2, 2026 | Lewis JoelPresident and CEO | Sell | 18,571 | $4.20 | $78K |
| Jan 2, 2026 | Callicutt Jack WChief Financial Officer | Sell | 13,914 | $4.20 | $58K |
| Jan 2, 2026 | Jamil KhurramChief Medical Officer | Sell | 13,055 | $4.20 | $55K |
| Dec 31, 2025 | Jamil KhurramChief Medical Officer | Sell | 8,125 | $4.07 | $33K |
| Dec 23, 2025 | Freeman Kevin DDirector | Buy | 5,500 | $3.55 | $20K |
| Dec 23, 2025 | Freeman Kevin DDirector | Buy | 5,500 | $3.55 | $20K |
| Dec 23, 2025 | Freeman Kevin DDirector | Buy | 5,500 | $3.55 | $20K |
| Dec 23, 2025 | Eldred KaryDirector | Buy | 700 | $3.73 | $3K |
| Dec 23, 2025 | Eldred KaryDirector | Buy | 700 | $3.73 | $3K |
| Dec 17, 2025 | Shlevin Harold H.Director | Sell | 19,793 | $7.04 | $139K |
| Dec 17, 2025 | Jamil KhurramChief Medical Officer | Sell | 8,500 | $7.04 | $60K |
| Dec 17, 2025 | Lewis JoelPresident and CEO | Sell | 7,829 | $7.06 | $55K |
| Dec 17, 2025 | Jamil KhurramChief Medical Officer | Sell | 6,463 | $7.04 | $45K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.